
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance
Clonal Cytopenia of Undetermined SignificanceCCUS Clonal Cytopenia of Undetermined SignificanceStudy researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Advanced Solid TumorThis first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

Stigma and Efficacy of Zhizhu Kuanzhong Capsules
Functional Gastrointestinal DisordersDyspepsia1 moreAntidepressants are effective in patients with functional dyspepsia (FD), however, the stigma related with FD and antidepressants could affect treatment adherence and efficacy. Zhi Zhu Kuan Zhong capsules (ZZKZ), a traditional Chinese medicine fomula, showed therapeutic potential for FD. The study was designed to investigate whether ZZKZ could alleviate stigma in FD and obtain identical effects in patients with refractory FD.

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Advanced Solid TumorObjectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes at OBD doses. Study Rationale: The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. Patient Population: Patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.

Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan
COVID-19Nasal washing (washout) followed by gargles with hypertonic saline (HSNIG) is believed to be effective in reducing the duration of illness in those with clinically suspected or confirmed COVID-19 being managed at home, and also is effective in reducing complications of COVID-19 and onward household transmission. This study plans to investigate whether the use of HSNIG performed by adults with symptoms consistent with COVID-19 reduces the duration of symptoms when compared to participants managed using standard care.

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Human Papilloma VirusHPV2 moreDoctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

Study of ATH434 in Participants With Multiple System Atrophy
Multiple System AtrophyThis study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments...
Multiple MyelomaThe study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after multiple prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination. The study is looking at several other research questions, including: How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma What side effects may happen from taking linvoseltamab together with another cancer treatment How much study drug is in your blood at different times Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment...
Joint InfectionThe purpose of this study is to learn about the safety and effects of PLG0206 for treating periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement, antibiotics and implant retention) surgical procedure for patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) .

NCPAP+MISA vs. NIPPV+MISA to NRDS:a Multicenter Randomized Study
Minimal Invasive Surfactant Administration in Two Different Non-invasive Ventilation Modes to NRDS InfantsBACKGROUND Treatment of neonatal respiratory distress syndrome(NRDS) with exogenous surfactant and mechanical ventilation made millions of preterm infants survived in neonatal intensive care unit (NICU). Endotracheal intubation surfactant administration is related to invasive intubation and short periods of positive pressure ventilation and implies the risk of lung injury.Recent studies have shown that minimally invasive surfactant administration(MISA) has more advantages than endotracheal intubation in premature infants with NRDS with spontaneous breathing (especially those with gestational age less than 30 weeks). It can reduce the time of invasive mechanical ventilation and reduce the incidence of bronchopulmonary dysplasia.The purpose of this study was to compare the efficacy of MISA in the treatment of NRDS in premature infants under the initial respiratory support mode of nasal continuous positive airway pressure(NCPAP) and Non-invasive positive pressure ventilation (NIPPV). DESIGN, SETTING, AND PARTICIPANTS The study was a multicenter, randomized, clinical, parallel-group study conducted between December 1st, 2021, and August 30,2023, in 16 level III neonatal intensive care units in China.Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. After transfer to NICU ward, infants were randomly assigned to NCPAP group and NIPPV group.Patients diagnosed with NRDS on non-invasive respiratory support (NIPPV or NCPAP) were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth.